MDTrials
ActiveSummary
MDTrials has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €364k and a net result of €56k. Its solvency ranks better than 95% of 213 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
Axes
Profitability87
Solvency100
Growth-
Track record85
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €30k at 30 days acceptable
Liquidity ample (current ratio 42.39; short-term debt: 2.1% and cash: 14.3% of total assets), and 2.1% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
97.9%
Return on assets
15%
Age of the figures
12 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 06-01-2026, 114 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
114 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2025, abbreviated schema
Equity
€364k
Total assets
€372k
Net result
€56k
Working capital
€329k
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Balance-sheet composition
Assets €372k
Fixed assets
€36k
Current assets
€337k
Equity and liabilities €372k
Equity
€364k
Debt
€8k
Debt finances 2.1% of the balance-sheet total.
Key figures and ratios
EBITDA
€88k
Cash flow
€65k
Current ratio
42.39
Debt to equity
0.02
ROE
15.3%
ROA
15.0%
Interest coverage
60.42
Debt ≤ 1 year
€8k
Income taxes
€27k
Filed annual accounts As filed with the NBB · 2025 · 43 lines
Balance sheet
Code2025
Assets
Total assets20/58€372k
Fixed assets21/28€36k
Tangible fixed assets22/27€35k
Plant, machinery and equipment23€1k
Furniture and vehicles24€34k
Financial fixed assets28€705
Current assets29/58€337k
Amounts receivable within one year40/41€22k
Trade receivables40€20k
Other amounts receivable41€2k
Current investments50/53€260k
Cash at bank and in hand54/58€53k
Deferred charges and accrued income490/1€511
Equity and liabilities
Total equity and liabilities10/49€372k
Equity10/15€364k
Contributions10/11€3k
Reserves13€361k
Distributable reserves133€361k
Amounts payable17/49€8k
Amounts payable within one year42/48€8k
Trade debts44€107
Suppliers440/4€107
Taxes, remuneration and social security45€6k
Taxes450/3€6k
Other amounts payable47/48€1k
Income statement
Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€10k
Other operating charges640/8€608
Gross operating margin9900€89k
Operating profit (loss)9901€79k
Financial income75/76B€6k
Recurring financial income75€6k
Financial charges65/66B€1k
Recurring financial charges65€1k
Profit (loss) for the period before taxes9903€83k
Income taxes67/77€27k
Profit (loss) for the period9904€56k
Profit (loss) for the period to be appropriated9905€56k
Appropriation of the result
Profit (loss) to be appropriated9906€56k
Transfer from equity791/2€30k
Transfer to equity691/2€56k
To other reserves6921€56k
Profit to be distributed694/7€30k
Return on contributions (dividend)694€30k
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2025 |
|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €10k |
| Other operating charges640/8 | €608 |
| Gross operating margin9900 | €89k |
| Operating profit (loss)9901 | €79k |
| Financial income75/76B | €6k |
| Recurring financial income75 | €6k |
| Financial charges65/66B | €1k |
| Recurring financial charges65 | €1k |
| Profit (loss) for the period before taxes9903 | €83k |
| Income taxes67/77 | €27k |
| Profit (loss) for the period9904 | €56k |
| Profit (loss) for the period to be appropriated9905 | €56k |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €372k | |
| Fixed assets21/28 | €36k | |
| Tangible fixed assets22/27 | €35k | |
| Plant, machinery and equipment23 | €1k | |
| Furniture and vehicles24 | €34k | |
| Financial fixed assets28 | €705 | |
| Current assets29/58 | €337k | |
| Amounts receivable within one year40/41 | €22k | |
| Trade receivables40 | €20k | |
| Other amounts receivable41 | €2k | |
| Current investments50/53 | €260k | |
| Cash at bank and in hand54/58 | €53k | |
| Deferred charges and accrued income490/1 | €511 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €372k | |
| Equity10/15 | €364k | |
| Contributions10/11 | €3k | |
| Reserves13 | €361k | |
| Distributable reserves133 | €361k | |
| Amounts payable17/49 | €8k | |
| Amounts payable within one year42/48 | €8k | |
| Trade debts44 | €107 | |
| Suppliers440/4 | €107 | |
| Taxes, remuneration and social security45 | €6k | |
| Taxes450/3 | €6k | |
| Other amounts payable47/48 | €1k | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €56k |
| + Depreciation and write-downs630 | €10k |
| Operating cash flow (approximation) | €65k |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2026
06-01
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
NBB filing
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brugge · 1 establishment unit since 2010
Ground area
4,213 m²
Building footprint
231 m²
Volume, LiDAR
1,786 m³
Parcel 31027F0176/00E002, Flanders · tallest building 22.6 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
MDTrials
since 20102.189.689.579
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 31027F0176/00E002 | Flanders | 4,213 m² | 1 · 231 m² | 22.6 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 · 1 entry · 211 EUR awarded · 211 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2022 | 1 | 211 EUR | 211 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Recognitions · licences · registrations
Legal Entity Identifier
9845009AEOAA43856A48
Similar companies · same sector, comparable size
CTI Clinical Trial and Consulting Services Belgium
BE 0566.984.596
Sint-Pieters-Woluwe · Eq €368,377
MY HEALTH INTERNATIONAL
BE 0684.959.659
Lummen · Eq €375,515
TAAG VENTURE CAPITAL EUROPE
BE 0795.880.644
Antwerpen · Eq €375,738
sil'innov
BE 0651.902.356
Courcelles · Eq €377,560
Neohla Bio
BE 0801.148.536
Antwerpen · Eq €347,377
Of 762 companies in sector 72101 we hold annual accounts for 481. 328 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded07-01-2010
Fiscal year end30-09
Abbreviation NL
MDT
Activities, NACEBEL 2025
72101Research and development on biotechnology
72109Other research and development on natural sciences
74999Other professional, scientific and technical activities
Scores and ratios are computed by Checked and are not a credit decision.